JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Morgan Healthcare Conference in San Francisco. In a presentation at the event, Davis painted a positive picture for the MSD's near-term success, noting that the company's plans to home in on the development of its late-stage pipeline, while adding that “value-adding transactions” could offer it a $70bn commercial growth opportunity. MSD's strategic ploy comes amid the looming patent cliff facing its immune checkpoint inhibitor, Keytruda (pembrolizumab), which became the best-selling drug on the market in 2024 after bringing in $29.5bn for the company. While GlobalData forecasts that Keytruda sales will continue to grow for the next couple of years – making $35.5bn for the company in 2027 – global patents covering the drug's market exclusivity are set to expire in 2028. This will likely result in significant losses for MSD, as Keytruda accounted for around 46% of the company's sales in 2024. GlobalData predicts sales of the drug in 2031 to drop to $19bn. To offset this impact,
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As [Yahoo! Finance]Yahoo! Finance
- Is Merck Stock A Trap At $110? [Forbes]Forbes
- Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance Canada]Yahoo! Finance Canada
- Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance]Yahoo! Finance
- Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings? [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- MRK's page on the SEC website